Larotrectinib

Description: Larotrectinib (LOXO-101) is an orally administered inhibitor of the TRK kinase, demonstrating high selectivity exclusively for the TRK family of receptors (IC50s = 2-20 nM). Target: Apoptosis, Trk receptor. Smiles: O[C@H]1CCN(C1)C(=O)Nc1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F. References: Doebele R C , Davis L E , Vaishnavi A , et al. An oncogenic NTRK fusion in a soft tissue sarcoma patient with response to the tropomyosin-related kinase (TRK) inhibitor LOXO-101[J]. Cancer Discovery, 2015, 5(10):1049-1057.